Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
Phytother Res. 2021 Jan;35(1):361-373. doi: 10.1002/ptr.6808. Epub 2020 Sep 1.
The plant Scutellaria barbata (SB) is commonly used as herbal medicines for treating cancer. The present pre-clinical study aimed to validate the Chinese Pharmacopoeia (CP) recommended dosages of SB water extract (SBW) in treating colon tumors. The content of chemical marker scutellarin in SBW was quantified using UPLC. Mice bearing human HCT116 xenografts or murine colon26 tumors received oral administration of SBW or scutellarin for 4 weeks. Results showed that SBW (615 and 1,230 mg/kg) and scutellarin (7 mg/kg) treatments significantly reduced human xenograft weights by 28.7, 36.9 and 28.8%, respectively. Lung metastasis area could be ameliorated after SBW (615 mg/kg) and scutellarin (7 mg/kg) treatments by 23.4 and 29.5%, respectively. Expressions of colon cancer metastasis-related proteins E-cadherin, Tspan 8 and CXCR4, as well as Src kinase in tumors were first shown to be regulated by SBW. Furthermore, in murine colon26 tumor-bearing mice, SBW (615 mg/kg) and scutellarin (7 mg/kg) treatments reduced the orthotopic tumor burden by 94.7% and lung metastatic tumor burden by 94.1%, respectively. Our findings provided evidences that SBW (at the mouse equivalent dosages to clinical dosages recommended by CP) could exert anti-tumor and anti-metastatic effects in colon cancer animal models.
植物半枝莲（SB）常被用作治疗癌症的草药。本临床前研究旨在验证中国药典（CP）推荐的 SB 水提取物（SBW）治疗结肠癌的剂量。采用 UPLC 定量测定 SBW 中化学标志物野黄芩苷的含量。携带人 HCT116 异种移植瘤或鼠结肠 26 肿瘤的小鼠接受 SBW 或野黄芩苷灌胃 4 周。结果表明，SBW（615 和 1230mg/kg）和野黄芩苷（7mg/kg）处理分别显著降低人异种移植瘤重量 28.7%、36.9%和 28.8%。SBW（615mg/kg）和野黄芩苷（7mg/kg）处理可分别改善肺转移面积 23.4%和 29.5%。首次表明 SBW 可调节肿瘤中结肠癌转移相关蛋白 E-钙粘蛋白、Tspan8 和 CXCR4 以及 Src 激酶的表达。此外，在携带鼠结肠 26 肿瘤的小鼠中，SBW（615mg/kg）和野黄芩苷（7mg/kg）处理分别使原位肿瘤负担减少 94.7%和肺转移性肿瘤负担减少 94.1%。我们的研究结果为 SBW（相当于 CP 推荐的临床剂量的小鼠等效剂量）在结肠癌动物模型中具有抗肿瘤和抗转移作用提供了证据。
